Timolumab (BTT1023 ) binds to human VAP-1, thereby blocking its function as an adhesion molecule. It also recognizes VAP-1 of other primates and rabbits but does not cross-react with rat or mouse. Timolumab (BTT1023 ) is potentially useful for the treatment and in vivo imaging of inflammatory conditions such as rheumatoid arthritis[2].
References:
[1]. Ahmad H Ali, et al. Novel treatments in primary sclerosing cholangitis. Clin Liver Dis (Hoboken). 2016 Nov 30;8(5):132-135.
[2]. Takayuki Inoue, et al. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem. 2013 Mar 1;21(5):1219-33.
[3]. Anu Autio, et al. Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.